Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular

Lilly and Eisai’s bid to secure NHS coverage of their Alzheimer’s therapies has entered a new phase, after an appeal of last year’s rejection by

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

ACIP is being broken up. No it’s not. On Thursday afternoon, an outspoken member of the CDC’s Advisory Committee on Immunization Practices claimed that the

In San Francisco a few weeks ago, I caught up with Nworah Ayogu, partner at Thrive Capital. Thrive had recently announced that it raised a